Table 1.

Anthropometric variables and serum concentrations of adipokines in patients with liver cirrhosis, patients with hepatocellular carcinoma, and healthy controls

Variable	Patients with HCC (n= 36)	Patients without HCC (n= 7)	Healthy controls (n= 10)	p
Age (years), median (Q1-Q3)	60.0 (57.0-67.0)	59.0 (51.5-70.0)	42.0 (32.2-59.8)	0.062
Sex, n(%) of women	10 (27.8%)	2 (28.6%)	5 (50.0%)	0.403
BMI (kg/m2), median (Q1-Q3)	29.0 (27.8-32.2)	29.0 (28.0-33.5)	26.0 (24.0-28.8)	0.115
Vaspin (ng/ml), median (Q1-Q3)	0.4 (0.2-0.6)	0.1 (0.1-0.2)	0.1 (0.1-0.2)	0.005*
Visfatin (ng/ml), mean ±SD	4.3 ±1.9	4.4 ±1.5	3.1 ±1.5	0.097
Irisin (μg/ml), median (Q1-Q3)	2.3 (1.7-3.5)	2.1 (2.0-2.9)	4.5 (2.5-4.7)	0.045*
Betatrophin (ng/ml), median (Q1-Q3)	36.5 (24.1-48.6)	25.0 (22.7-43.6)	12.3 (11.0-12.7)	< 0.001**
Insulin (ng/ml), median (Q1-Q3)	1.0 (0.5-1.3)	0.7 (0.4-1.6)	0.4 (0.4-0.6)	0.008**

Q1-Q3 – interquartile range, BMI – body mass index, HCC – hepatocellular carcinoma

^*significant difference (Dunn’s test, p < 0.05) between healthy controls and patients with HCC

^**significant difference (Dunn’s test, p < 0.05) between healthy controls and both patients with and without HCC